Metal-Organic Frameworks for Drug Deliver
Metal-Organic Frameworks for Drug Deliver
Synthetic Biology
Patented MOF-based nanocarriers for targeted and controlled release of therapeutics.
Metal-Organic Frameworks (MOFs) are a class of porous materials that have gained significant attention in recent years due to their potential applications in drug delivery. The patented MOF-based nanocarriers utilize the unique properties of MOFs to provide targeted and controlled release of therapeutics. The MOF-based nanocarriers are composed of a metal node and an organic linker, which are combined to form a crystalline structure with high surface area and tunable pore size. This allows for the loading of therapeutic agents, such as small molecules, proteins, or nucleic acids, into the pores of the MOF. The loaded MOFs can then be functionalized with targeting moieties, such as antibodies or peptides, to direct the nanocarriers to specific sites within the body.The release of therapeutics from the MOF-based nanocarriers can be controlled through various mechanisms, including pH, temperature, and enzymatic triggers. For example, the MOF structure can be designed to degrade in response to acidic conditions, releasing the therapeutic agent in the acidic environment of a tumor or inflammatory site. Alternatively, the MOF can be engineered to release its cargo in response to specific enzymes, such as proteases or lipases, that are present at the target site.The use of MOF-based nanocarriers for targeted and controlled release of therapeutics offers several advantages over traditional drug delivery systems. The high surface area and pore volume of MOFs allow for high loading capacities and efficient release of therapeutics, while the tunable properties of the MOF enable precise control over the release kinetics. Additionally, the biocompatibility and biodegradability of MOFs make them an attractive alternative to traditional materials used in drug delivery.The patented MOF-based nanocarriers have the potential to revolutionize the field of drug delivery, enabling the targeted and controlled release of therapeutics with improved efficacy and reduced side effects. The technology has applications in a wide range of therapeutic areas, including oncology, infectious disease, and regenerative medicine, and is currently being explored in preclinical and clinical studies.
Cancer treatment: The patented MOF-based nanocarriers can be designed to target specific cancer cells, releasing therapeutic agents in a controlled manner to maximize efficacy and minimize side effects.
Gene therapy: These nanocarriers can be engineered to deliver genetic material, such as DNA or RNA, to specific cells or tissues, enabling precise gene editing or expression.
Infectious disease treatment: MOF-based nanocarriers can be used to deliver antibiotics, antivirals, or other antimicrobial agents directly to the site of infection, reducing the risk of resistance and side effects.
Regenerative medicine: The controlled release of growth factors, stem cells, or other therapeutic agents from MOF-based nanocarriers can promote tissue repair and regeneration.
Immunotherapy: These nanocarriers can be designed to deliver immunomodulatory agents, such as vaccines or checkpoint inhibitors, to specific immune cells, enhancing the body's natural response to disease.
Neurological disorder treatment: MOF-based nanocarriers can be engineered to cross the blood-brain barrier, delivering therapeutic agents directly to the brain or spinal cord to treat conditions such as Alzheimer's, Parkinson's, or multiple sclerosis.
Wound healing: The controlled release of growth factors, antibiotics, or other therapeutic agents from MOF-based nanocarriers can accelerate wound healing, reducing the risk of infection and promoting tissue repair.
Personalized medicine: The versatility of MOF-based nanocarriers enables the development of personalized treatment strategies, tailored to an individual's specific needs and disease profile.
World Economic Forum
Audio and visual technology
View Patent